ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2012
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03210766 (Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain), which is not on this map. Cited by 192 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain
Who cites it
192 citing papers in PubMed, 2 syntheses or guidelines pooled it, 462 citations in OpenAlex.
- Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.Molecular psychiatry · 2026Pooled it
- Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Medicinal cannabis plant extract (NTI164) modifies epigenetic, ribosomal, and immune pathways in paediatric acute-onset neuropsychiatric syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Trial
- Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-ExperimentalCannabis and cannabinoid research · 2024Trial
- The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial.Psychopharmacology · 2023Trial
- Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study.Translational psychiatry · 2022Trial
- Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training.Nutrients · 2021Trial
- Cannabidiol (CBD) differentially shapes systemic cytokines and transcriptomic profiles in the liver and spleen: insights from a male mouse model.Molecular genetics and genomics : MGG · 2026Article
- Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease.Metabolic brain disease · 2026Article
- Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2026Review
- The Potential of Cannabidiol for the Treatment of Psychosis: Endocannabinoid Regulation of Serotonergic Neurotransmission via Serotonin 5-HT1A/2A Receptors.Neurochemical research · 2026Review
- Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus.Brain sciences · 2026Article
- Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CBPsychopharmacology · 2026Article
- Cannabidiol at the crossroads: panacea, placebo, or problem?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Phytocannabinoids as epigenetic regulators: bridging DNA methylation and redox homeostasis in glioblastoma.Journal of applied genetics · 2026Article
- Cannabidiol as a treatment for cocaine use disorder: a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mechanistic Pathways Linking Cannabidiol, Hemp Seed Oil and Black Sesame Oil in Hyperarousal Insomnia: A Narrative Review.Clocks & sleep · 2026Review
- Efficacy and safety of cannabidiol (CBD) on reducing pain and functional impairment associated with exercise-induced muscle injury: a randomized placebo-controlled feasibility trial.Journal of cannabis research · 2026Article
- Marijuana Use and Its Impact on Outpatient Anesthesia.Anesthesia progress · 2026Review
132 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) is a major phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound Δ(9)-tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear that CBD has therapeutic potential over a wide range of non-psychiatric and psychiatric disorders such as anxiety, depression and psychosis. Although the pharmacological effects of CBD in different biological systems have been extensively investigated by in vitro studies, the mechanisms responsible for its therapeutic potential are still not clear. Here, we review recent in vivo studies indicating that these mechanisms are not unitary but rather depend on the behavioural response being measured. Acute anxiolytic and antidepressant-like effects seem to rely mainly on facilitation of 5-HT1A-mediated neurotransmission in key brain areas related to defensive responses, including the dorsal periaqueductal grey, bed nucleus of the stria terminalis and medial prefrontal cortex. Other effects, such as anti-compulsive, increased extinction and impaired reconsolidation of aversive memories, and facilitation of adult hippocampal neurogenesis could depend on potentiation of anandamide-mediated neurotransmission. Finally, activation of TRPV1 channels may help us to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD. Considering its safety profile and wide range of therapeutic potential, however, further studies are needed to investigate the involvement of other possible mechanisms (e.g. inhibition of adenosine uptake, inverse agonism at CB2 receptor, CB1 receptor antagonism, GPR55 antagonism, PPARγ receptors agonism, intracellular (Ca(2+)) increase, etc.), on CBD behavioural effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.